Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | MMP1 | P03956 | 2/20 | 0.46 |
| ▸ | MMP2 | P08253 | 2/20 | 0.46 |
| ▸ | MMP9 | P14780 | 2/20 | 0.46 |
| ▸ | MMP8 | P22894 | 2/20 | 0.46 |
| ▸ | MMP13 | P45452 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 2/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31667740 | 1.00 | TSHR (0.58) | TSHRMAPK1MMP1MMP2MMP9 | |
| SCHEMBL627966 | 0.85 | VCAM1 (0.51) | TDP1ALDH1A1VCAM1POLB | |
| SCHEMBL3334862 | 0.85 | TSHR (0.62) | TSHRMAPK1MMP1MMP2MMP9 | |
| SCHEMBL550266 | 0.83 | TSHR (0.60) | TSHRMAPK1MMP1MMP2MMP9 | |
| SCHEMBL1117240 | 0.82 | TSHR (0.50) | TSHRMAPK1TDP1CYP3A4LMNA | |
| SCHEMBL10660218 | 0.81 | TSHR (0.58) | TSHRMAPK1MMP1MMP2MMP9 | |
| SCHEMBL10270605 | 0.81 | TSHR (0.58) | TSHRMAPK1MMP1MMP2MMP9 | |
| SCHEMBL5068488 | 0.81 | TSHR (0.58) | TSHRMAPK1MMP1MMP2MMP9 | |
| SCHEMBL6211032 | 0.81 | TSHR (0.58) | TSHRMAPK1MMP1MMP2MMP9 | |
| SCHEMBL28876320 | 0.80 | TSHR (0.56) | TSHRMAPK1MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2026-03-19 | — | — | US | disclosed |
| EP-2646448-B1 | MACROCYCLIC KINASE INHIBITORS | OSI PHARMACEUTICALS LLC (US) | 2017-08-30 | — | — | EP | disclosed |
| US-9133224-B2 | Macrocyclic kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2015-09-15 | — | — | US | disclosed |
| US-9108939-B2 | (1, 1, 1,3,3,3-hexafluoro-2 hydroxypropan-2-yl) phenyl derivative, pharmaceutical compositions thereof and their use for the treatment of atherosclerosis | MERCK SHARP & DOHME B.V. (NL) | 2015-08-18 | — | — | US | disclosed |
| US-9096624-B2 | Amino pyrimidine anticancer compounds | OSI Pharmaceuticals, LLC (US) | 2015-08-04 | — | — | US | disclosed |
| EP-2493855-B1 | (1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl derivatives, pharmaceutical compositions thereof and their use for the treatment of atherosclerosis | MERCK SHARP & DOHME (NL) | 2014-02-26 | — | — | EP | disclosed |
| EP-2646448-A1 | MACROCYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2013-10-09 | — | — | EP | disclosed |
| US-20130261086-A1 | MACROCYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2013-09-05 | — | — | US | disclosed |
| US-8399433-B2 | Amino pyrimidine anticancer compounds | OSI Pharmaceuticals, LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120238574-A1 | (1, 1, 1,3,3,3 -HEXAFLUORO-2 HYDROXYPROPAN- 2 -YL) PHENYL DERIVATIVE, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS | N.V. ORGANON (NL) | 2012-09-20 | — | — | US | disclosed |
| EP-2493855-A1 | (1,1, 1,3, 3, 3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL) PHENYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS | MSD Oss B.V. (NL) | 2012-09-05 | — | — | EP | disclosed |
| WO-2012074951-A1 | MACROCYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2012-06-07 | — | — | WO | disclosed |
| EP-2438056-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| WO-2011051282-A1 | (1,1, 1,3, 3, 3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL) PHENYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS | N.V. ORGANON (NL) | 2011-05-05 | — | — | WO | disclosed |
| WO-2010141406-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | NAMPT, NNMT, SARM1 | TSHR 363/4885MAPK1 1908/4885MMP1 3536/4885 |
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | TSHR 4171/4885MAPK1 290/4885MMP1 4373/4885 |
| US-20130261086-A1 | MACROCYCLIC KINASE INHIBITORS | PTK2, SRC, PTK2B | TSHR 2146/4885MAPK1 68/4885MMP1 1975/4885 |
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | TSHR 4171/4885MAPK1 290/4885MMP1 4373/4885 |
| US-20120238574-A1 | (1, 1, 1,3,3,3 -HEXAFLUORO-2 HYDROXYPROPAN- 2 -YL) PHENYL DERIVATIVE, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS | TGFB1, FPR1, TGFB2 | TSHR 3684/4885MAPK1 665/4885MMP1 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.